Dr. John L. Faessel
ON THE MARKET
Commentary and Insights
Anatabine and its effect on aging
“...the implications for what this means to millions of individuals are limitless.” *
From the patent application:
“Anatabine can be administered to reduce and/or reduce senescence (i.e., ageing).”
Ok – there’s a lot of science here and terms like “telomeres” and the “Hayflick limit”** are outside the common lexicon, but hang in there as the essence of this work may well have gargantuan implications for the life expectancy of humankind.
Leonard Hayflick** has studied the aging process for more than thirty years. He is known for discovering that human cells divide for a limited number of times in vitro . This is known as the Hayflick limit.
Useful here to once again review...
“Making false patent claims could mean big fines for companies found liable under the false patent marking statute. The Federal Circuit has distinguished a century old precedent, and now every article falsely marked with a patent number is subject to the maximum fine, rather than each decision to falsely mark.1 By law the maximum fine is $500 for each item. This means a batch of 100,000 falsely marked products could face fines of $50,000,000, with qui tam litigants eligible to collect half.2” (Source law firm: Bracewell & Giuliani LLP. Yes, that’s Rudy Giuliani’s law firm...)
Now some necessary background from the “Genetic Science Learning Center” at the University of Utah.
“Inside the center or nucleus of a cell, our genes are located on twisted, double-stranded molecules of DNA called chromosomes. At the ends of the chromosomes are stretches of DNA called telomeres which protect our genetic data, make it possible for cells to divide, and hold some secrets as to how we age and get cancer.”
“Telomeres have been compared with the plastic tips of shoelaces because they protect chromosome ends from fraying and sticking to each other, which would scramble an organism’s genetic information to cause cancer, other diseases or death.”
“Yet each time a cell divides, the telomeres get short. When they get too short, the cell no longer can divide and becomes inactive or senescent or dies. This process is associated with aging, cancer and higher risk of death. So telomeres also have been compared to a bomb fuse.”
Now cue up inflammation - and how it affects telomere length (a Google search found 1,020,000 results):
Scientists have known for some time that inflammation is the primary accelerator of telomere loss and that inflammation-induced telomere attrition speeds the pace of biologic aging.
And if we slow the process of telomere loss we could extend our theoretical lifetimes towards the thought to be maximum limit of 120 years or so. Thus it’s a given that reducing inflammation will certainly delay the onset of many age related infirmities.
One interesting study demonstrated that aging adults who showed telomere shortening over a 2.5 year period were three times more likely to die from heart disease than matched older individuals without telomere shortening. http://www.impactaging.com/papers/v1/n1/full/100007.html
Now let’s look at the patent application: Pages 11 & 12
 Anatabine may have a positive effect on telomere length. Thus, in some embodiments anatabine can be administered to reduce and/or reverse cellular senescence (i.e., aging). Conditions associated with cellular senescence can be treated. For example, anatabine can be administered to reduce and/or reduce senescence of:
8 age related examples follow:
1. cells with replicative capacity in the central nervous system, including astrocytes, endothelial cells, and fibroblasts which play a role in age-related diseases as Alzheimer's disease, Parkinson's disease, Huntington's disease, and stroke;
2. cells with finite replicative capacity in the integument, including fibroblasts, sebaceous gland cells, melanocytes, keratinocytes, Langerhan's cells, and hair follicle cells, which may play a role in age-related diseases of the integument such as dermal atrophy, elastolysis and skin wrinkling, sebaceous gland hyperplasia, senile lentigo, graying of hair and hair loss, chronic skin ulcers, and age-related impairment of wound healing;
3. cells with finite replicative capacity in the articular cartilage, such as chondrocytes and lacunal and synovial fibroblasts, which play a role in degenerative joint disease;
4. cells with finite replicative capacity in the bone, such as osteoblasts and osteoprogenitor cells, which play a role in osteoporosis;
5. cells with finite replicative capacity in the immune system such as Band T lymphocytes, monocytes, neutrophils, eosinophils, basophils, NK cells and their respective progenitors, which may play a role in age-related immune system impairment;
6. cells with a finite replicative capacity in the vascular system including endothelial cells, smooth muscle cells, and adventitial fibroblasts, which may play a role in age-related diseases of the vascular system including atherosclerosis, calcification, thrombosis, and aneurysms;
7. cells with a finite replicative capacity in the eye such as pigmented epithelium and vascular endothelial cells which may play an important role in age-related macular degeneration; and
8. cells with abnormal proliferative capacity, such as cancer cells.
In summary: In the face of anatabine, not only is inflammation safely curtailed, but―telomere loss is decelerated―hence life spans are prolonged.
Moreover, levels of inflammation are easily tested for. Elevated blood levels of C-reactive protein [CRP], a marker of systemic inflammation, requires only a simple blood test and the results are generally included in blood panels of individuals over 30-years old when the testing of cholesterol levels usually begins. A Google search of C-reactive protein [CRP] brought up 5,520,000 results.
Here is what the patent says:
 Anatabine can be used to reduce elevated blood levels of inflammatory markers such as CRP.
Connect the dots here... A tidal wave of science is cresting about the benefits of anatabine / Anatabloc™, buoyed even higher by the numerous anecdotal stories of healings and improvements of conditions that continue to flood into what has become a gripping narrative. Those new to the story are generally skeptical. But the deeper one delves into the particulars of the science the more one becomes fascinated by the possibilities of what could be a true "panacea" remedy or even a potion to ward off unspecified ailments, including aging. Astonishingly, the quantum leap here is the ability of anatabine to throttle back only the harmful immune system components of inflammation without destructive immune system suppression; this is / will be a breakthrough of historic proportions in the treatment of inflammatory conditions.
* On August 31, 2011 at the monthly meeting of Partners in Healthcare of Virginia, Jonnie Williams, Star Scientific CEO stated, “Anatabloc™ (anatabime) is a non-prescription anti-inflammatory product that revolutionizes inflammatory control as we know it. The studies that are already public show what the anatabine compound is capable of, and the implications for what this means to millions of individuals are limitless.”
Listen to the Podcast: The Future of Aging by University of Utah researcher Dr. Richard Cawthon discuss how his research on telomere length and human aging may change how we age and perhaps even one day keep us forever young. Listen Here (22:40)
Also excellent on Telomeres:
Aging, or senescence, is the major cause of suffering, disease, and death in Western civilization. Gerontology, also called biogerontology, is the science that studies the aging process to prevent age-related disease and degeneration, preserve health, and prolong human life.
* Leonard Hayflick (born May 20, 1928), Ph.D., is Professor of Anatomy at the University of California, San Francisco, School of Medicine, and was Professor of Medical Microbiology at Stanford University School of Medicine. He is a past president of the Gerontological Society of America and was a founding member of the council of the National Institute on Aging (NIA).
Disclosure: I'm an investor in Star Scientific shares and have bought shares on the open market and have no affiliation with the company other than as a shareholder.
If you missed my previous reports—more specific in detail and scope on each of these themes—or wish to receive my Best Ideas for 2012, send a request to: Dr.Faessel@onthemar.com
To view the new Anatabloc™ website; http://anatabloc.com/